Read More Pharma Industry News Merck’s enlicitide slashes LDL-C by 55.8%: Could this daily pill replace PCSK9 injections? Merck’s enlicitide cuts LDL-C by over 55% in Phase 3 trial. Could it become the first oral PCSK9 inhibitor to transform ASCVD treatment? bySrinathNovember 9, 2025